{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:36:36Z","timestamp":1791502596539,"version":"4.3.4"},"reference-count":27,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T00:00:00Z","timestamp":1703203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2023,12,4]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Dyspnoea and cough can have a profound impact on the lives of patients with pulmonary fibrosis. We investigated the effects of nintedanib on the symptoms and impact of pulmonary fibrosis in patients with progressive pulmonary fibrosis (PPF) in the INBUILD trial using the Living with Pulmonary Fibrosis (L-PF) questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients had a fibrosing interstitial lung disease (ILD) (other than idiopathic pulmonary fibrosis) of &gt;10% extent on high-resolution computed tomography (HRCT) and met criteria for ILD progression within the prior 24\u2005months. Patients were randomised 1:1 to receive nintedanib or placebo. Changes in L-PF questionnaire scores from baseline to week 52 were assessed using mixed models for repeated measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 663 patients were treated. Compared with placebo, there were significantly smaller increases (worsenings) in adjusted mean L-PF questionnaire total (0.5<jats:italic>versus<\/jats:italic>5.1), symptoms (1.3<jats:italic>versus<\/jats:italic>5.3), dyspnoea (4.3<jats:italic>versus<\/jats:italic>7.8) and fatigue (0.7<jats:italic>versus<\/jats:italic>4.0) scores in the nintedanib group at week 52. L-PF questionnaire cough score decreased in the nintedanib group and increased in the placebo group (\u22121.8<jats:italic>versus<\/jats:italic>4.3). L-PF questionnaire impacts score decreased slightly in the nintedanib group and increased in the placebo group (\u22120.2<jats:italic>versus<\/jats:italic>4.6). Similar findings were observed in patients with a usual interstitial pneumonia-like fibrotic pattern on HRCT and in patients with other fibrotic patterns on HRCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on changes in L-PF questionnaire scores, nintedanib reduced worsening of dyspnoea, fatigue and cough and the impacts of ILD over 52\u2005weeks in patients with PPF.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.00752-2023","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T11:45:11Z","timestamp":1703245511000},"page":"2300752","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":58,"title":["Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis"],"prefix":"10.1183","volume":"63","author":[{"given":"Marlies","family":"Wijsenbeek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Swigris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-874X","authenticated-orcid":false,"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus B.","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"2024102103212903000_63.2.2300752.1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0075-2018"},{"key":"2024102103212903000_63.2.2300752.2","doi-asserted-by":"crossref","first-page":"799912","DOI":"10.3389\/fmed.2022.799912","article-title":"The burden of progressive-fibrosing interstitial lung diseases","volume":"9","author":"Cottin","year":"2022","journal-title":"Front Med"},{"key":"2024102103212903000_63.2.2300752.3","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00681-2021"},{"key":"2024102103212903000_63.2.2300752.4","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.202105-1193ST","article-title":"Patient-centered outcomes research in interstitial lung disease: an official American Thoracic Society research statement","volume":"204","author":"Aronson","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103212903000_63.2.2300752.5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0026-2021"},{"key":"2024102103212903000_63.2.2300752.6","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1164\/rccm.202002-0415OC","article-title":"Development and initial validation analyses of the Living with Idiopathic Pulmonary Fibrosis questionnaire","volume":"202","author":"Swigris","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103212903000_63.2.2300752.7","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00145-2020"},{"key":"2024102103212903000_63.2.2300752.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2024102103212903000_63.2.2300752.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04538-2020"},{"key":"2024102103212903000_63.2.2300752.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-001167"},{"key":"2024102103212903000_63.2.2300752.11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-020-1298-1","article-title":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS trials","volume":"21","author":"Kreuter","year":"2020","journal-title":"Respir Res"},{"key":"2024102103212903000_63.2.2300752.12","doi-asserted-by":"crossref","first-page":"SI43","DOI":"10.1093\/rheumatology\/keac325","article-title":"Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease","volume":"62","author":"Kreuter","year":"2023","journal-title":"Rheumatology"},{"key":"2024102103212903000_63.2.2300752.13","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12989"},{"key":"2024102103212903000_63.2.2300752.14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12931-019-1020-3","article-title":"The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry","volume":"20","author":"Kreuter","year":"2019","journal-title":"Respir Res"},{"key":"2024102103212903000_63.2.2300752.15","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-017-0621-y"},{"key":"2024102103212903000_63.2.2300752.16","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.chest.2019.11.042","article-title":"Disease severity and quality of life in patients with idiopathic pulmonary fibrosis: a cross-sectional analysis of the IPF-PRO Registry","volume":"157","author":"O'Brien","year":"2020","journal-title":"Chest"},{"key":"2024102103212903000_63.2.2300752.17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12931-021-01790-0","article-title":"Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease","volume":"22","author":"Chen","year":"2021","journal-title":"Respir Res"},{"key":"2024102103212903000_63.2.2300752.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.06.018"},{"key":"2024102103212903000_63.2.2300752.19","doi-asserted-by":"crossref","first-page":"1601788","DOI":"10.1183\/13993003.01788-2016","article-title":"Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis","volume":"49","author":"Swigris","year":"2017","journal-title":"Eur Respir J"},{"key":"2024102103212903000_63.2.2300752.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000278"},{"key":"2024102103212903000_63.2.2300752.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2024102103212903000_63.2.2300752.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2024102103212903000_63.2.2300752.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102103212903000_63.2.2300752.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2024102103212903000_63.2.2300752.25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1874306402014010022","article-title":"Effects of nintedanib on quantitative lung fibrosis score in idiopathic pulmonary fibrosis","volume":"14","author":"Lancaster","year":"2020","journal-title":"Open Respir Med J"},{"key":"2024102103212903000_63.2.2300752.26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024102103212903000_63.2.2300752.27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2022","journal-title":"Lancet Respir Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00752-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:38:47Z","timestamp":1740382727000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00752-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,1]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1183\/13993003.00752-2023"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00752-2023","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]}}}